Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per ...
The company signed a $229-per-share agreement in March to take control of Seagen, which had previously been linked to a possible takeover by MSD. Getting the merger over the finish line has required some concessions, notably that Pfizer has agreed to donate all the rights of royalties from...
Pfizer intends to use the net proceeds of the offering as part of the financing for Pfizer’s proposed acquisition of Seagen Inc. (the “Merger”). The Notes, other than any issuance of 40-year notes, are expected to be subject to a special mandatory redemption under certain circumstances ...